Blog

Biomarkers Market Companies, Advances and Trends

The biomarkers market size was estimated at US$ 82.35 billion in 2023 and is projected to grow to US$ 366.6 billion by 2034, rising at a compound annual growth rate (CAGR) of 14.54% from 2024 to 2034. The rising incidences of chronic disorders, growing research and development, and increasing investments drive the market.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5322

Biomarkers Market: Tracing the Disease

Biomarkers or biological markers are molecules found in blood, body fluids, or tissues that explain what is happening in a cell or organism. They are used to perform clinical assessments and monitor and predict health states in individuals. For instance, high levels of lead in the bloodstream may indicate a need to test for nervous system and cognitive disorders, especially in children. Biomarkers play a crucial role in determining relationships between environmental exposures, human biology, and disease. A biomarker can also act as a diagnostic measure that examines the organ function or other aspects of health when introduced into an organism. Biomarkers can also aid in disease prognosis by providing information about the patient’s overall outcome, regardless of any treatment or therapeutic intervention.

The rising incidence and prevalence of chronic disorders potentiates the demand for finding the root cause of the disease and aiding in novel drug discovery and development. The growing research and development boost biomarkers research. The market is also driven by increasing investments from both government and private organizations, and collaborations augment the market.

Biomarkers Market Trends

• In October 2024, SanboxAQ, an AI and quantum technology company, announced the collaboration with Sanofi to locate biomarkers using large quantitative models (LQMs) to gain a better understanding of human biology. The collaboration was made to support scientists’ ability to promote trust throughout investigational medicines and clinical development.
• In October 2024, MEDiC Life Sciences announced the collaboration with Hanmi Pharmaceutical. The collaboration was made to use MEDiC’s MCAT platform to identify cancer biomarkers for one of Hanmi’s clinical assets.
• In August 2024, the University of Nevada, Las Vegas, received a $3.2 million investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to develop a biomarker observatory to diagnose and monitor Alzheimer’s disease.

Regional Insights

North America Leads with Strong Government Support

In 2023, North America held the largest share of the biomarkers market. The region benefits from cutting-edge research, supportive government policies, increasing chronic disease rates, and the presence of major players. For instance, the US FDA promotes the integration of biomarkers in medical product development and approval, accelerating the progress of promising new therapies. Canada’s ongoing national human biomonitoring survey, led by Statistics Canada in partnership with Health Canada and the Public Health Agency of Canada, further supports the market. Additionally, the region’s continuous focus on drug discovery contributes to the market’s growth.

Asia-Pacific’s Rapid Growth Driven by Rising Chronic Diseases

The Asia-Pacific region is expected to experience the fastest growth in the biomarkers market in the coming years. This is fueled by a rise in chronic diseases, a growing focus on research and development, and increased investments and collaborations. The increasing rates of cancer and neurological and immunological disorders are boosting demand for biomarkers, particularly in disease diagnosis and drug discovery. For example, China has over 15 million people aged 60 and above living with dementia, while India reports 8.8 million cases. Japan is also seeing significant numbers, with around 3.9 million cases of dementia in 2023. The rising geriatric population, rapid urbanization, and shifting demographics are driving substantial demand for biomarker research in the region.

Segmental Insights

Safety Biomarkers Take the Lead

In 2023, the safety biomarkers segment dominated the global biomarkers market. These biomarkers help identify the potential toxicity of a drug or environmental exposure, playing a crucial role in early clinical trials. By assessing the safety of therapeutics early in development, they help determine whether a drug should progress from preclinical to clinical testing.

Efficacy Biomarkers Show Rapid Growth Potential

Efficacy biomarkers, which indicate a drug’s therapeutic effects, are projected to grow the fastest in the coming years. These biomarkers track early disease progression or pharmacological responses, providing valuable insights into a drug’s potential effectiveness.

Cancer Remains the Leading Disease Focus

Cancer continues to be the dominant disease segment in the biomarkers market, driven by the increasing incidence of cancer, its complexity, rapid mutations, and the growing demand for personalized medicine. Biomarkers are essential in cancer diagnosis, prognosis, and predicting the likelihood of disease recurrence, regardless of the treatment approach.

Neurological Diseases Set for Significant Growth

The neurological diseases segment is expected to experience strong growth in the coming years, fueled by an aging population and the rising prevalence of disorders such as Alzheimer’s and Parkinson’s diseases. As these conditions become more common, the need for biomarkers to assist in diagnosis and treatment is increasing.

Drug Discovery & Development Remains the Leading Application

The drug discovery and development segment was the largest in 2023, as biomarkers provide crucial insights into disease mechanisms. This understanding aids in the development of new drugs. Growing awareness, alongside increased investments and collaborations, is expected to continue driving growth in this area.

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/biomarkers-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5322

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Sterile Disposable Vacuum Blood Collection Tube Market Shares and Developments

The sterile disposable vacuum blood collection tube market was estimated at US$ 2.63 billion in 2023 and is projected to grow to US$ 5.84 billion by 2034, rising at a compound annual growth rate (CAGR) of 7.53% from 2024 to 2034. The increasing number of biochemical and immunological tests and the rising prevalence of chronic disorders drive the market.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5321

Sterile Disposable Vacuum Blood Collection Tube Market Overview

Vacuum blood collection tubes are sterile, sealed tubes used to collect blood samples from patients. They are made of either glass or plastic and have a color-coded rubber stopper at one end and a needle at the other. These tubes are designed for single use only and are disposed of after use to maintain sterility and prevent contamination. Depending on the type of test to be performed on the blood sample, these tubes also contain additives such as anticoagulants, clot activators, or preservatives. The color of the stopper indicates the additives in the tube.

The increasing number of laboratory tests such as biochemical, immunological, diabetes, and tuberculosis tests potentiates the use of blood collection tubes. The growing demand for sterile and disposable tubes to prevent cross-contamination among patients and increasing investments in healthcare infrastructure boost the market. Favorable government policies and increasing awareness to prevent chronic disorders increase the demand for frequent laboratory tests.

The Sterile Disposable Vacuum Blood Collection Tube Market is experiencing steady growth driven by various factors in the healthcare and medical sectors. Key trends influencing the market include:

• Increased Demand for Safe and Convenient Blood Collection: The growing emphasis on patient safety, minimal contamination risks, and user-friendly blood collection methods are driving the demand for sterile disposable vacuum blood collection tubes. These tubes are favored for their convenience, quick processing, and lower risk of cross-contamination, making them a preferred choice in hospitals, diagnostic centers, and laboratories.
• Technological Advancements: Continuous innovation in the design and materials of vacuum blood collection tubes is enhancing their performance. Newer products offer improved accuracy, reliability, and better sealing mechanisms to ensure optimal blood sample integrity.
• Rise in Chronic Diseases: The increasing prevalence of chronic diseases, such as diabetes, cardiovascular diseases, and cancer, is expanding the need for frequent blood tests, boosting demand for blood collection tubes.
• Global Health Initiatives: As health systems globally focus on expanding diagnostic services, particularly in emerging economies, the demand for blood collection tubes is growing, both in quantity and sophistication. Governments and organizations are also promoting healthcare infrastructure upgrades, which directly supports market expansion.
• Regulatory Standards and Compliance: Strict regulatory frameworks around healthcare products are encouraging manufacturers to invest in high-quality production and ensure their products meet safety and efficacy standards, driving market growth.
• Disposable Products Trend: The growing trend toward single-use, disposable products in healthcare reduces the risks of contamination and infection, reinforcing the demand for sterile vacuum blood collection tubes.
• Sustainability Concerns: With increasing attention to sustainability, manufacturers are exploring eco-friendly materials and recycling practices for blood collection tubes. The market is likely to see an increasing shift toward biodegradable or recyclable options.
• COVID-19 Impact: The COVID-19 pandemic spurred a significant rise in diagnostic testing, including blood collection, driving a temporary surge in demand for sterile blood collection tubes. This trend is expected to stabilize post-pandemic but may continue to support long-term market growth.

Recent Development in the Sterile Disposable Vacuum Blood Collection Tube Market

• In December 2023, BD (Becton, Dickinson and Company) announced that it received 510(k) clearance from the US FDA for its novel blood collection device, BD MiniDraw Capillary Blood Collection System. The system is a less-invasive technique that withdraws a small blood volume from a fingerstick and produces lab-quality results for some of the most commonly ordered blood tests.

Top Companies in the Sterile Disposable Vacuum Blood Collection Tube Market

• Ajosha Bio Teknik
• Becton, Dickinson and Company
• Biomall
• Bio-x Diagnostics
• CML Biotech
• GPC Medical, Ltd.
• Greiner Bio-One International
• Hawach Scientific
• KS Medical
• Medtronic
• Quantum Biomedicals
• Sanli Medical
• Sarstedt AG & Co. KG
• Sekisui Chemical Co. Ltd.
• Terumo Corporation

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field –  https://www.towardshealthcare.com/table-of-content/sterile-disposable-vacuum-blood-collection-tube-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5321

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Plasma Fractionation Market Trends and Companies

The global plasma fractionation market size was estimated at US$ 32.75 billion in 2023 and is projected to grow to US$ 72.86 billion by 2034, rising at a compound annual growth rate (CAGR) of 7.54% from 2024 to 2034. The rising therapeutic demand for plasma is boosting the plasma fractionation market.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5320

Market Overview

Plasma fractionation is a complex process to separate blood plasma into individual components, predominantly protein which includes clotting factors, albumin, immunoglobulins and fibrinogens, other components are enzymes and antibodies with phenomenal therapeutical values. Plasma fractionation is widely used in pharmaceutical research to treat chronic diseases. The worldwide rising demand for plasma derivatives due to increased immune disease, coagulation disorders and genetic defects is fuelling the market growth.

Plasma Fractionation Market Trends

• In September 2024, Epsilogen, a global leading biotechnology company in London, expanded its financing round by raising $16.4 million to process the development of its immunoglobulin E (IgE) antibodies for cancer treatment. The investment was sourced by the British Patient Capital, the Novartis Venture Fund, Epidarex Capital, the 3B Future Health Fund and ALSA Ventures.
• In June 2024, Biotest, a global company that supplies plasma protein products and biotherapeutic drugs, controlled by Grifols, a globally leading healthcare company, received FDA approval for marketing Yimmugo – a treatment of primary humoral immunodeficiency (PI) in patients 2 years of age or older.
• In July 2024, the Independent Health and Aged Care Pricing Authority announced Activity Based Funding (ABF) for home-delivered subcutaneous immunoglobulin (SCIg) infusion therapy. This therapy is a non-admitted patient service performed by patients at their homes without a healthcare provider.

Plasma Fractionation Market Trends

In September 2024, Epsilogen, a leading biotechnology company based in London, raised $16.4 million in a financing round to advance its development of immunoglobulin E (IgE) antibodies for cancer treatment. The funds were secured from major investors including British Patient Capital, the Novartis Venture Fund, Epidarex Capital, the 3B Future Health Fund, and ALSA Ventures. This investment highlights the growing interest in plasma-based therapies for cancer treatment.

In June 2024, Biotest, a global supplier of plasma protein products and biotherapeutic drugs, which is now controlled by Grifols, a global healthcare leader, received FDA approval for its Yimmugo product. Yimmugo is a treatment for primary humoral immunodeficiency (PI) in patients aged two years and older, marking an important development in the plasma fractionation sector.

In July 2024, the Independent Health and Aged Care Pricing Authority introduced Activity Based Funding (ABF) for home-delivered subcutaneous immunoglobulin (SCIg) infusion therapy. This new service enables patients to administer their therapy at home without the need for healthcare providers, further emphasizing the trend toward decentralized treatments in plasma fractionation.

Chromatography: The Future of Plasma Fractionation

Chromatography-based methods for plasma separation are rapidly gaining traction in the plasma fractionation market. These techniques offer several advantages, including improved purity and the ability to create novel therapeutic products. Plasma contains over 120 different proteins, and when these proteins are carefully separated and concentrated, they can be used to produce life-saving treatments for various conditions like immune deficiencies and bleeding disorders.

Currently, the majority of plasma fractionation technology still relies on the original ethanol-based protocols, primarily used to isolate albumin. However, for the development of new plasma-derived therapeutics, chromatographic techniques are crucial. These techniques can isolate even trace proteins, preserving the integrity of sensitive proteins like coagulation factors, anticoagulants, and protease inhibitors. Ion-exchange chromatography (IEC), in particular, allows proteins to be preserved in their original pH and ionic conditions, ensuring that even fragile proteins remain intact during the fractionation process.

Sepsis Risk: A Major Market Restraint

One of the significant challenges in plasma fractionation is the potential risk of sepsis, a life-threatening condition that can arise from certain plasma protein imbalances. A study published in Science Translational Medicine identified a pattern in the plasma profiles of ICU patients who developed sepsis. Sepsis occurs when the body’s response to infection becomes dysregulated, leading to multiple organ failure. It is a major cause of death, with approximately 50,000 deaths occurring annually in the United Kingdom due to sepsis.

The study involved analyzing plasma samples from 16,000 patients, measuring protein levels through tandem mass spectrometry and liquid chromatography. The results provided a general plasma protein profile, which can help identify patients who are at risk of developing sepsis. This discovery underscores the importance of monitoring plasma protein levels during fractionation processes to minimize the risk of sepsis and other complications in patients receiving plasma-derived therapies.

Top Companies in Plasma Fractionation Market

• Syntegon
• CSL Behring
• Grifols Therapeutics
• Mitsubishi Tanabe
• Octapharma AG
• Hualan Bio
• Kedrion S.p.A
• Takeda Pharmaceutical Company Ltd.
• LFB Group
• Intas Pharmaceuticals Ltd.
• Biotest AG
• Bio Product Laboratory Ltd.

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/plasma-fractionation-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5320

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Resorbable Nerve Conduits Market Insights

The global resorbable nerve conduits market size was estimated at US$ 2.31 billion in 2023 and is projected to grow to US$ 5.28 billion by 2034, rising at a compound annual growth rate (CAGR) of 7.8% from 2024 to 2034. The rising demand to treat nerve injuries by reducing the risk of inflammation and regenerating nerve with the presence of foreign body is increasing the adoption of resorbable nerve conduit market.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5319

Market Overview

Resorbable nerve conduit devices may be derived from natural or synthetic materials. Utilization of a resorbable PGA (polyglycolic acid) tube filled with collagen sponge restores both sensory and motor electrophysiological functions. This technique is also considered superior to an autograft technique. The combination of a resorbable synthetic tube with biological factors leads the way in advancing the future. This strategy encourages and hastens nerve growth. The incorporation of several neurotrophic factors has demonstrated the capability to promote axonal growth in vitro. However, its use in vivo is still undiscovered.

Resorbable Nerve Conduits Market Trends

• In September 2024, the US Food and Drug Administration (FDA) granted breakthrough therapy designation (BTD) to Neuraptive Therapeutics Inc.’s NTX-001 for the treatment of patients with peripheral nerve injury requiring repair. The BTD is awarded on the promising result of the Phase II NEUROFUSE study and as per US regulations.
• In January 2024, Nalu Medical, a privately held commercial medical device company, announced $65 million in equity financing to support their minimal invasive neurostimulation product. The company has received FDA approval for spinal cord stimulation and peripheral nerve stimulation technology to treat patients with chronic neuropathic pain.

Emerging Biomaterial: Opportunity of Resorbable Nerve Conduits Market

The innovation of biodegradable nanomaterial is expected to be beneficial for manufacturing new nerve conduits. Combining an adequate density and 3D structure to design a scaffold with Schwann Cells can replicate Bands of Büngner to enhance the regrowth of axons in the peripheral nerve injury. To eliminate the immune rejection. Schwann Cells can be withdrawn from either umbilical stem cells or other tissues such as autologous adipose tissue. This collaboration application of tissue, cell and genetic engineering can provide promising results in better functional recovery of peripheral nerve injury.

Disposable Diabetes Lancets Market Companies & Shares

The disposable diabetes lancets market size was estimated at US$ 1.19 billion in 2023 and is projected to grow to US$ 1.9 billion by 2034, rising at a compound annual growth rate (CAGR) of 4.33% from 2024 to 2034. The increasing demand for point-of-care diagnostics, the rising prevalence of diabetes, and technological advancements drive the market.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5318

Disposable Diabetes Lancets Market: Simplifying Blood Glucose Testing

Lancets are small, sterile needles used to draw a tiny blood sample by pricking the skin, typically from a finger. These are designed for one-time use and are available in two types: standard lancets and safety lancets. Lancets are essential for monitoring blood glucose levels, especially for patients with diabetes. As the demand for point-of-care diagnostics increases, the use of lancets has become more widespread.

With the rising prevalence of type I and type II diabetes, there is a greater need for regular blood glucose monitoring. This has driven the demand for lancets, especially with the introduction of advanced devices designed for easier and less painful blood collection.

Disposable Diabetes Lancets Market Trends

In May 2024, Roche Diabetes Care India announced the local manufacturing of its glucose monitoring device, Accu-Chek Active, to meet the growing demand for diabetes care in India. The initiative is in partnership with Sanmina-SCI India Pvt. Ltd. and Parekh Integrated Services Pvt. Ltd. to enhance accessibility.

In August 2024, Medical Technology and Devices (MTD) acquired Ypsomed’s Pen Needles and Blood Glucose Monitoring Systems businesses. MTD is also investing significantly in establishing production facilities for pen needles and lancets in Europe.

The UK’s National Health Service (NHS) recommends that newly diagnosed diabetes patients check their blood sugar every 3 months, and at least every 6 months once their condition is stable.

Segmental Insights

By Type: The safety lancets segment is expected to experience substantial growth in the coming years. Safety lancets are a safer alternative to standard ones as they are designed to prevent needlestick injuries. These lancets can penetrate to a specific depth, making them more personalized to individual patient needs. Continuous advancements in technology are driving this segment’s growth.

By Application: The hospital and clinic segment held the largest share of the disposable diabetes lancets market in 2023. With an increasing number of diabetes patients and the availability of proper disposal facilities, hospitals and clinics are the primary users of disposable lancets. The presence of trained healthcare professionals in these settings reduces the risk of injury or infection during testing.

Recent Developments

In April 2024, Drawbridge Health received 510(k) clearance from the US FDA for its NanoDrop Lancet, an advanced at-home blood sampling device. The device is approved for over-the-counter (OTC) use, allowing individuals to collect blood samples from the upper arm.

In March 2023, Pip Diabetes launched painless, single-use lancets designed for a clean, comfortable blood sample. These lancets are engineered for precision, minimizing pain and vibration during the fingerstick process.

Top Companies in the Disposable Diabetes Lancets Market

• A. Menarini Diagnostics
• Acon Diabetes Care
• AdvaCare Pharma
• Arkray Healthcare Pvt. Ltd.
• BioCare Corporation
• CVS Pharmacy
• Drawbridge Health
• Genteel
• Hoffman La-Roche Ltd.
• Owen Mumford
• Pip Diabetes
• SD Biosensor Healthcare Pvt. Ltd.

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/disposable-diabetes-lancets-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5318

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Compounded Topical Drug Market Companies and Developments Announcements

The compounded topical drug market was estimated at US$ 4.27 billion in 2023 and is projected to grow to US$ 6.78 billion by 2034, rising at a compound annual growth rate (CAGR) of 4.29% from 2024 to 2034. The demand for personalized medicines and the increasing incidence of skin disorders drive the market.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5317

Compounded Topical Drug Market: Customized Care

Compounded drugs are sterile or nonsterile drugs or nutrients formulated in a licensed pharmacy, outsourcing facility, or other healthcare-related facility. They are not FDA-approved for safety and effectiveness. Compounding involves combining, mixing, or altering ingredients tailored to the needs of the patients. According to the American Chronic Pain Association, the most common compounded medications are topical medications. Topical drugs are semisolid preparations or transdermal patches on the skin, mucous membranes, or cavities. Topical preparations treat pain for injured workers with a specific need. Topical agents are often prepared by mixing the powdered tablet in a petroleum base to form ointments.

The increasing incidences of skin disorders potentiate the demand for compounded topical drugs. According to the WHO, 1.8 billion people are estimated to be affected by skin conditions at any point in time. The demand for personalized medicines and the ease of preparation of topical drugs boost the market. If a person is allergic to any dye or ingredient, compounded preparations can be made without the dye or ingredient. The market is also driven by increasing drug shortages due to rising population and demand.

Trends in the Compounded Topical Drug Market

In May 2022, Medisca, a leading supplier of pharmaceutical compounding products, acquired DIFFUSIMAX and DIFFUSIMAX10 liposomal bases from Maxima Pharmaceuticals. These products are used in preparing compounded topical formulations and include all intellectual property assets from Maxima.

In April 2022, the U.S. FDA added four substances to its 503B Bulks List, which includes APIs determined to be necessary for compounding by outsourcing facilities. The new APIs added are diphenylcyclopropenone, glycolic acid, squaric acid dibutyl ester, and trichloroacetic acid, all for use in topical formulations.

Calgary Co-op’s 2023 sales were reported at approximately $1.3 million, marking a $0.1 million increase from 2022, with net earnings of $16,704.

Automation: The Future of the Compounded Topical Drug Market

Recent advancements in technology, such as artificial intelligence (AI), are transforming the compounding process by introducing automation. This shift improves efficiency, accuracy, and safety. Traditional pharmacy compounding is a labor-intensive process requiring careful human input, but AI-powered systems can automate the entire procedure, streamlining workflows and reducing the risk of errors.

AI can enhance precision by accurately measuring and dispensing ingredients, as well as enabling real-time monitoring to identify and correct mistakes early on. This automation not only helps minimize human errors but also frees up time for pharmacists to focus on patient care and medication counseling, leading to improved health outcomes.

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/compounded-topical-drug-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5317

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Human Coagulation Factor VII Market Companies and Developments

The global human coagulation factor VII market size was estimated at US$ 1.21 billion in 2023 and is projected to grow to US$ 1.82 billion by 2034, rising at a compound annual growth rate (CAGR) of 3.74% from 2024 to 2034. Human coagulation factor VII is used to prevent bleeding, and growing cases of accidents and trauma are increasing the demand for coagulation factor VII.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5300

Human Coagulation Factor VII Market Overview

Human coagulation factor VII is a critical clotting agent used to prevent excessive bleeding, particularly in individuals with hemophilia. This condition can lead to life-threatening bleeding during surgeries or following trauma and accidents. In such cases, external doses of coagulation factors like factor VII are needed to manage bleeding. As the incidence of hemophilia increases and more surgeries are performed globally, the demand for human coagulation factor VII is expected to rise.

Market Trends

In August 2024, the U.S. Food and Drug Administration (FDA) resolved a shortage of the 8-milligram vial of Novo Nordisk’s NovoSeven RT coagulation factor VIIa (recombinant), which had been ongoing since February 2024.

Additionally, in March 2024, TiumBio Co., Ltd. filed a Clinical Trial Application (CTA) with the Spanish and Italian Medicines Agencies to begin a Phase 1b study for TU7710, a novel recombinant activated factor VII (rFVIIa) aimed at treating hemophilia patients with inhibitors.

Market Opportunity: Growing Geriatric Population

The increasing elderly population is another key factor driving the growth of the human coagulation factor VII market. Older individuals are more likely to undergo surgeries due to age-related health issues. As factor VII plays a crucial role in preventing excessive bleeding during surgeries, the growing number of older patients will contribute to the rising demand for this product.

Challenges Facing the Human Coagulation Factor VII Market

Despite its importance, factor VII treatments are often expensive, which may limit access for patients, particularly in low-income countries. The complex regulatory process and long approval times for new treatments can also delay the availability of new products. Additionally, the potential side effects of factor VII therapies may discourage some patients and healthcare providers from choosing this treatment.

Regional Insights

North America led the human coagulation factor VII market in 2023. This is largely due to the region’s high number of surgeries, strong government support, a growing healthcare and pharmaceutical industry, and active blood donation initiatives that ensure a steady supply of coagulation factors. The U.S. and Canada are major contributors to market growth, with the U.S. holding the largest share.

For instance:

• In the U.S., approximately 33,000 men have hemophilia, and around 3,442 Canadians were diagnosed with Hemophilia A in 2022.
• Surgical expenses account for over 25% of healthcare-related costs in the U.S. With around 40 to 50 million major surgeries performed annually in the U.S. and 20 million in Europe, the demand for coagulation factor VII remains high.

Asia Pacific is expected to experience the fastest market growth during the forecast period, driven by an expanding population and an increasing number of surgeries. Coagulation factor VII is crucial for preventing excessive bleeding during surgeries, further boosting its demand in the region.

For example:

• By 2050, the elderly population in India is projected to grow significantly, reaching over 20% of the total population.
• In 2023, China had over 297 million people aged 60 or older, and this number is expected to surpass 500 million by 2050.
• In 2022, Chinese hospitals conducted approximately 82.7 million inpatient surgeries, with significant regional differences in surgical volume.
• India, with an estimated 30 million surgeries annually, will also see an increased demand for coagulation factors, especially given the country’s large population and high surgical procedure rates.

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/human-coagulation-factor-vii-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5300

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Thrombopoietin Receptor Agonists Market Size Shares and Trends

The global thrombopoietin receptor agonists market, valued at $1.85 billion in 2023, is projected to reach $3.74 billion by 2034, with a CAGR of 6.6%. Demand is driven by these drugs’ role in boosting platelet counts to reduce health risks.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5297